D-livering the message: The importance of vitamin D status in chronic liver disease  by Kitson, Matthew T. & Roberts, Stuart K.
ReviewD-livering the message: The importance of vitamin D status
in chronic liver disease
Matthew T. Kitson, Stuart K. Roberts⇑
Department of Gastroenterology, The Alfred, Melbourne, AustraliaSummary recognition that vitamin D has immunomodulatory, anti-Vitamin D is synthesized predominantly in the liver and func-
tions as an important secosteroid hormone with pleiotropic
effects. While its key regulatory role in calcium and bone homeo-
stasis is well established, recently there is increasing recognition
that vitamin D also regulates cell proliferation and differentia-
tion, and has immunomodulatory, anti-inﬂammatory and anti-
ﬁbrotic properties. These non-skeletal effects are relevant in the
pathogenesis and treatment of many causes of chronic liver dis-
ease. Vitamin D deﬁciency is frequently present in chronic liver
disease and may predict non-response to antiviral therapy in
chronic hepatitis C. Small studies suggest that vitamin D supple-
mentation improves sustained viral response rates, while
1a-hydroxylase polymorphisms and vitamin D-binding protein
are also implicated in therapeutic outcomes. Vitamin D deﬁ-
ciency also closely relates to the severity of non-alcoholic fatty
liver disease (NAFLD) and is implicated in the pathogenesis of
insulin resistance, a key factor in the development of NAFLD. In
preclinical studies, phototherapy and vitamin D supplementation
ameliorate NAFLD histopathology, while vitamin D is a powerful
anti-ﬁbrotic against thioacetamide liver injury. In liver transplant
recipients severe vitamin D deﬁciency predicts, and vitamin D
supplementation prevents, acute cellular rejection. The role of
vitamin D in the activation and regulation of both innate and
adaptive immune systems may explain its importance in the
above liver diseases. Further prospective studies are therefore
warranted to investigate the therapeutic impact of vitamin D
supplementation in chronic liver disease.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Vitamin D is an important secosteroid hormone with pleiotropic
effects (Table 1). While its role in the regulation of calcium and
bone homeostasis is well established, recently there is increasingJournal of Hepatology 20
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role in the regulation of cell proliferation and differentiation.
These extraskeletal effects are relevant in the pathogenesis and
treatment of many causes of chronic liver disease.Vitamin D synthesis and metabolism
Vitamin D undergoes a 3-step activation process before it inter-
acts with the vitamin D receptor. The majority of circulating vita-
min D is synthesized in the skin as a result of exposure to
sunlight. The initial step involves ultraviolet-B radiation (wave-
length 290–315 nm) converting the cholesterol metabolite
7-dehydrocholesterol into previtamin D3 in the lower epidermis,
which is rapidly converted to vitamin D3 in a heat-dependent
process. However, excessive sunlight exposure does not cause
vitamin D intoxication because excess vitamin D3 is destroyed
by sunlight [1]. Only a small proportion of vitamin D is obtained
from dietary sources such as fatty ﬁsh, eggs, UV-irradiated mush-
rooms, supplements, and artiﬁcially fortiﬁed foods (Table 2). Die-
tary-derived vitamins D2 (ergocalciferol) and D3 (cholecalciferol)
are absorbed via a bile-acid dependent process whereby vitamin
D is incorporated into micelles in the intestinal lumen, then
absorbed by enterocytes and packaged into chylomicrons that
are then transported to the venous circulation via lymphatic
drainage. Vitamin D from both skin synthesis and dietary sources
can either be stored in adipocytes or undergo 25-hydroxylation in
the liver. This process is mediated by the 25-hydroxylases, which
are cytochrome P450 isoforms that include the important micro-
somal CYP2R1 and the mitochondrial CYP27A1 enzymes. This
produces the main circulating, though biologically inactive, form
25-hydroxyvitamin D [25(OH)D], or calcidiol, which has a long
half-life of 2–3 weeks and is therefore used to assess vitamin D
status. The vast majority (88%) of serum 25(OH)D is bound to
vitamin D-binding protein (DBP), which is also known as Gc or
the group-speciﬁc component of globulin. DBP is a 58 kDa
a-macroglobulin almost exclusively synthesized by the liver
and a member of the albumin gene family located on chromo-
some 4, with high sequence homology to albumin and a-fetopro-
tein [2]. It is highly polymorphic, having three common isoforms,
Gc1F, Gc1S, and Gc2, that display marked racial variation [3],
with the Gc1F isoform having the highest afﬁnity for vitamin D
metabolites. DBP has anti-inﬂammatory and immunomodulatory
functions independent of its role as the carrier of vitamin
D [4,5].12 vol. 57 j 897–909
Table 1. Pleiotropic effects of vitamin D.
Target Action
Hepatic
Inhibits in vitro HCV replication in a dose-dependent manner [30-32]
Supplementation may improve SVR rate in HCV [36-38]
Vitamin D-binding protein is one of 3 metaproteins associated with SVR in HCV [40]
Supplementation/phototherapy improves liver histology in preclinical studies of NAFLD [58]
Supplementation decreases risk of acute rejection post-transplantation [125]
Extra-hepatic
Mortality Supplementation decreases mortality by 7% [16]
Calcium and bone homeostasis Enhances Ca and PO4 absorption from small intestine [6]
Suppresses PTH secretion [6]
Induces osteoclast maturation [6]
Pancreas/adipocytes BMI inversely associated with 25(OH)D level [46]
Normal vitamin D status associated with 67% lower prevalence of metabolic syndrome [47]
Activates transcription of insulin gene [50]
Supplementation improves insulin sensitivity and lowers risk of developing type 2 diabetes [52-54]
Immune system
Innate Activates macrophage TLR response to TB infection [95]
Hastens sputum culture conversion in pulmonary TB in those with tt TaqI VDR allele [100]
Downregulates expression of TLR2, TLR4 and TLR9 [107-110]
Necessary for NK cell development and function [114]
Enhances NK cell cytotoxicity [115]
Promotes tolerant DC phenotype by suppressing DC maturation [116]
Enhances secretion of IL10 and decreases secretion of IL12 from DCs [122]
Adaptive Activates naïve T cells [117]
Inhibits proliferation of Th1 lymphocytes [118]
Shifts balance to a Th2 phenotype [119]
Increases Treg cells [120,121]
Inhibits Th17 cell development [121]
Supplementation decreases risk of developing MS in women [85] and type 1 diabetes in children [86]
Carcinogenesis Higher 25(OH)D levels associated with lower incidence of colorectal adenoma [135]
Sunlight exposure associated with reduced risk of NHL [145]
Supplementation prevents liver fibrosis in preclinical studies [62,63]
ReviewThe ﬁnal step in the synthesis of vitamin D is 1a-hydroxyl-
ation that predominantly occurs in the proximal tubule of the
kidney but also to a lesser extent in lymphocytes and parathyroid
tissue. It is mediated by 1a-hydroxylase (CYP27B1) that produces
the active form 1a,25-dihydroxyvitamin D [1a,25(OH)2D] or
calcitriol, which is also highly bound to DBP (85%) [2] and has a
half-life of only 4 h. 1a,25(OH)2D is the ligand that activates
the vitamin D receptor (VDR). This then forms a heterodimer with
the retinoid X receptor that acts as a transcription factor that
binds to vitamin D response elements in the promoter region of
target genes. 1a-hydroxylation is under the inﬂuence of factors
such as serum phosphate and calcium concentration, parathyroid
hormone (PTH), ﬁbroblast growth factor 23 and genetic polymor-
phisms of CYP27B1. 1a,25(OH)2D acts in a negative feedback loop
to decrease its own synthesis and increase the expression of
25-hydroxyvitamin D-24-hydoxylase (CYP24A1), which catabo-
lizes 1a,25(OH)2D into calcitroic acid, a biologically inert agent
excreted in the bile (Fig. 1).898 Journal of Hepatology 201VDR is expressed in most tissues and cells of the human body,
including liver, pancreas, and several immune cells including
monocytes, macrophages, T lymphocytes, B lymphocytes, natural
killer (NK) cells, and dendritic cells (DC), with expression most
abundant on the epithelial cells of the gastrointestinal tract. As
a transcription factor activated by 1a,25(OH)2D, VDR directly or
indirectly regulates the expression of more than 200 genes that
inﬂuence cell proliferation, differentiation and apoptosis, as well
as immunomodulation and angiogenesis [6]. Studies in VDR null
mice highlight the broad physiologic function of vitamin D [7].Vitamin D deﬁciency
Vitamin D deﬁciency is broadly deﬁned as a serum 25(OH)D level
<50 nmol/L (<20 ng/ml). Levels between 75 and 125 nmol/L
(30–50 ng/ml) are considered optimal as PTH levels rise when
25(OH)D is <75 nmol/L (30 ng/ml); hence, levels between 502 vol. 57 j 897–909
Table 2. Sources of vitamin D.
Vitamin D2 (ergocalciferol):
UV-irradiated mushrooms
Oral supplements
Vitamin D3 (cholecalciferol):
Ultraviolet B light (290-315 nm): the major source of vitamin D3
Salmon
Mackerel
Tuna
Sardines
Eel
Cod liver oil
Eggs
Oral supplements
Artificially fortified foods (e.g. milk, cereals, bread, margarine)
Artificially fortified foods (e.g. milk, cereals, bread, margarine)
Fatty fish:
JOURNAL OF HEPATOLOGYand 75 nmol/L (20–30 ng/ml) are increasingly recognized to rep-
resent vitamin D insufﬁciency [8–11]. Using these deﬁnitions, it
is estimated that more than 1 billion people worldwide are either
vitamin D deﬁcient or insufﬁcient [12], with the elderly and those
with chronic medical illness most at risk. However, even amongst
healthy young people, vitamin D deﬁciency and insufﬁciency are
still common [13–15]. A meta-analysis of 18 randomized-
controlled trials involving 57,311 participants shows that sub-
jects randomized to receive vitamin D supplementation, at a
mean daily dose of 528 IU, have a statistically signiﬁcant 7%
reduction in all-cause mortality over a mean follow-up duration
of 5.7 years [16]. Vitamin D deﬁciency has a deleterious clinical
impact on a number of important medical conditions (Table 3).Vitamin D and chronic liver disease
The liver is a pivotal organ in the synthesis of vitamin D. It is the
site where 25-hydroxylation occurs and where the vast majority
of DBP is synthesized. In those with chronic liver disease (CLD)
the prevalence of vitamin D insufﬁciency (<75 nmol/L) is almost
universal, with vitamin D deﬁciency (<50 nmol/L) present in
around two-thirds of subjects. Even in the absence of cirrhosis,
vitamin D deﬁciency is present in the majority of subjects. In
those with cirrhosis, the prevalence of severe vitamin D deﬁ-
ciency (<25 nmol/L) increases with increasing severity of syn-
thetic liver dysfunction [17,18]. Notably, in those about to
undergo liver transplantation, the frequency of 25(OH)D and
1a,25(OH)2D deﬁciency is 84% and 77%, respectively, with trans-
plantation resulting in a marked increase in 25(OH)D,
1a,25(OH)2D, and DBP levels [19].
The high prevalence of vitamin D deﬁciency in this population
occurs regardless of the etiology of liver disease [20,21]. Synthetic
liver dysfunction is not entirely responsible, as vitamin D deﬁ-
ciency is still highly prevalent in those with non-cirrhotic liver
disease [17]. 25(OH)D levels normalize after oral or parenteralJournal of Hepatology 201administration of vitamin D in patients with cirrhosis, indicating
that 25-hydroxylation is preserved in this patient population
[22,23]. Serum DBP levels, which play a critical role in the trans-
port and bioavailability of vitamin D, are moderately decreased in
cirrhosis [24,25]. However, as only 5% of DBP binding sites are
occupied at any one time with vitamin D metabolites [2], pro-
found liver dysfunction is required for low DBP levels to exert a
signiﬁcant contributing role to vitamin D deﬁciency in chronic
liver disease.
Vitamin D deﬁciency in CLD is likely to result from a number
of mechanisms. In addition to those described above, those
patients with a chronic medical illness such as liver disease are
more likely to have lower levels of sunlight exposure and/or inad-
equate dietary intake of vitamin D. Moreover, luminal absorption
of dietary sources of vitamin D may be hindered by intestinal
edema complicating portal hypertension and/or impaired bile
salt dependent micellar incorporation due to cholestasis.Vitamin D and chronic hepatitis C
Around 170 million people worldwide have chronic hepatitis C
(CHC) infection [26], causing a substantial burden of chronic liver
disease globally [27]. Vitamin D deﬁciency is more prevalent in
CHC subjects than healthy controls, even in those with minimal
liver ﬁbrosis. The majority of subjects with CHC are vitamin D
deﬁcient (<50 nmol/L) with 25% having severe deﬁciency
(<25 nmol/L) [28,29]. Current understanding of the mechanisms
underlying the high prevalence of vitamin D deﬁciency in CHC
is incomplete.
Nevertheless, recent evidence suggests that vitamin D may
impact upon clinical outcomes and treatment response. Funda-
mental to this are several in vitro studies showing that vitamin
D inhibits hepatitis C virus (HCV) replication in a dose-dependent
manner [30–32]. Moreover, an association between baseline vita-
min D status and treatment response to pegylated-interferon
(PEG-IFN) and ribavirin (RBV) has recently been established
(Fig. 2). Pre-treatment vitamin D deﬁciency is reportedly an inde-
pendent predictor of failure to achieve a sustained virologic
response (SVR) in HCV genotype 1 (HCV-1), [28,33], and 2/3
infection [29]. However, 25(OH)D level is not associated with
SVR in HCV–HIV co-infection [34]. In HCV-1 infection, the
rs12979860 C/T polymorphism upstream of the interleukin-28B
(IL28B) gene on chromosome 19 is the strongest pre-treatment
predictor of SVR [35]. Baseline vitamin D status is independent
of, but additive to, the IL28B genotype in predicting SVR in
HCV-1. The highest SVR rate occurs in subjects who have the
favorable CC genotype and 25(OH)D levels >50 nmol/L [33].
To date, there is limited data evaluating vitamin D supple-
mentation in CHC treatment. Two small prospective randomized
controlled studies from Israel showed that those subjects who
received vitamin D3 supplementation of 2000 IU/day, targeting
a 25(OH)D level >80 nmol/L in addition to PEG-IFN/RBV combina-
tion therapy, had higher rates of rapid virologic response (RVR;
44% vs. 17%, p <0.001), complete early virologic response (cEVR;
94% vs. 48%, p <0.001) and SVR (86% vs. 42%; OR 2.5, 95% CI
2.0-4.9, p <0.001) in HCV-1 [36] and SVR (95% vs. 77%, p <0.001)
in HCV-2/3 infection [37] compared to subjects treated with stan-
dard therapy. Moreover, recipients of vitamin D3 supplementa-
tion were less likely to be relapsers or non-responders to
antiviral therapy, and had improved insulin resistance indices2 vol. 57 j 897–909 899
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Fig. 1. Vitamin D synthesis.
Review[36]. Similarly, a small retrospective Italian study showed vita-
min D3 supplementation improved SVR rate in the treatment of
recurrent hepatitis C post liver transplantation (53.3% vs. 18.5%,
p = 0.02) [38]. It remains unclear whether these improvements
in the clearance of HCV with vitamin D supplementation are
the result of an alteration in innate and/or adaptive immune
function, or are mediated via improvement in insulin resistance.
Large, prospective, placebo-controlled studies are thus required
to assess the impact of vitamin D supplementation on viral
response in CHC treatment. However, these studies now seem
unlikely to occur in the new and rapidly evolving era of direct
acting viral therapy.900 Journal of Hepatology 201Vitamin D status also reportedly correlates with liver histol-
ogy in CHC. Patients with vitamin D deﬁciency have a higher
grade of hepatic necroinﬂammation [28,33], more advanced
ﬁbrosis stage [28,29,34] and may possibly have more rapid ﬁbro-
sis progression [39]. At a cellular level, vitamin D deﬁciency is
associated with downregulation of the 25-hydroxylase enzyme
CYP27A1 in liver tissue. This may have pathogenetic relevance,
given the established inverse relationship between CYP27A1
expression and the severity of necroinﬂammatory activity [28].
The above ﬁndings highlight the potential role that proteins
and enzymes involved in the synthesis and metabolism of vita-
min D may have in liver inﬂammation and response to anti-viral2 vol. 57 j 897–909
Table 3. Clinical impact of vitamin D deﬁciency.
Target Action
Hepatic
HCV Non-responsiveness to interferon-based therapy [28,29,33]
Downregulation of 25-hydroxylase CYP27A1 in liver [28]
NAFLD
Increased hepatic expression of TLR2, TLR4 and TLR9 [59], which are implicated in NAFLD pathogenesis 
[111,112]
Extra-hepatic
Insulin sensitivity Associated with presence of insulin resistance [48]
Predicts future development of insulin resistance and hyperglycaemia [49]
Impaired pancreatic β-cell function [50,51]
Immune system Increased risk of M. tuberculosis infection [78,92-94]
Increased population incidence of autoimmune diseases such as MS [84]
Carcinogenesis Increased risk of colon [136-139], breast [140-142] and prostate cancer [143,144]
More advanced fibrosis stage and higher inflammatory grade [28,29,33]
May be associated with rapid fibrosis progression [39]
More severe steatosis, inflammation and fibrosis [55,59]
Deficiency and HCV
• Independent predictor of failure to achieve 
  RVR, EVR and SVR in genotype 1-3
• Effect independent of IL28B genotype
Supplementation and HCV
• Inhibits in vitro viral replication
• May improve RVR, cEVR and SVR rate in HCV-1
• May improve SVR in HCV-2/3 and recurrent HCV
Deficiency and liver histology
in HCV 
• Higher necroinflammatory grade
• More advanced fibrosis stage
• Faster fibrosis progression
Genetic polymorphisms and HCV
• AA genotype of CYP27B1 polymorphism 
  associated with higher SVR rate and 
  1α, 25(OH)2D level in HCV-1 
• VDR bAt[CAA] - haplotype and CC genotype of 
  Apal allele associated with rapid fibrosis progression
  and cirrhosis
Fig. 2. Vitamin D and hepatitis C.
JOURNAL OF HEPATOLOGYtherapy. Genetic variation in the rs10877012 A/C polymorphism
in the promoter region of the 1a-hydroxylase enzyme CYP27B1,
but not the rs10735810 FokI VDR polymorphism, is associated
with SVR in HCV-1 infection. Subjects with the AA genotype have
higher SVR rate and 1a,25(OH)2D level than those with the AC or
CC genotype [29], suggesting a key role of vitamin D in CHC infec-
tion. Moreover, a recently published proteomic study has shown
vitamin DBP to be one of three metaproteins associated with SVR
[40]. DBP levels are signiﬁcantly lower in subjects with signiﬁ-
cant or advanced ﬁbrosis (METAVIR F2-4) compared with those
with absent or minimal ﬁbrosis (F0/1) and healthy controls
[41,42].
Thus, vitamin D deﬁciency appears to be common in CHC and
may be associated with adverse outcomes such as lowerJournal of Hepatology 201treatment response, more advanced ﬁbrosis stage and increased
severity of necroinﬂammation. It remains, however, uncertain
as to whether vitamin D supplementation improves the SVR rate
in patients receiving combination anti-viral therapy with PEG-
IFN and RBV. Still, the ﬁndings of a signiﬁcant association
between the CYP27B1 rs10877012 A/C polymorphism, higher
1a,25(OH)2D levels, and SVR rate, as well as the association
between vitamin D-binding protein and SVR suggest that higher
25(OH)D and 1a,25(OH)2D levels directly improve the virologic
response to PEG-IFN and RBV therapy, presumably by impacting
on the downstream regulation of vitamin D target gene transcrip-
tion. DBP determines how much free 25(OH)D substrate is avail-
able for 1a-hydroxylase as well as the amount of free
1a,25(OH)2D ligand available to activate the VDR and inﬂuences2 vol. 57 j 897–909 901
Review
downstream gene transcription. Hepatic 1a-hydroxylase activity
levels therefore represent a major additional factor regulating
1a,25(OH)2D concentration in the liver.Vitamin D and non-alcoholic fatty liver disease
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifes-
tation of the metabolic syndrome. It is the most common liver
disease in the developed world, with a prevalence of 20–30%
[43]. Thirty percent of subjects with NAFLD have histologic evi-
dence of non-alcoholic steatohepatitis (NASH) [44] and are at risk
of disease progression and development of cirrhosis. The patho-
genesis of NAFLD is yet to be fully elucidated, but insulin resis-
tance (IR) is implicated as the key mechanism leading to
hepatic steatosis. Apart from lifestyle modiﬁcation that results
in signiﬁcant weight loss [45], there is currently no safe, effective
therapy for NASH.
Vitamin D levels decrease by 1.3 nmol/L with each 1 kg/m2
increase in body mass index (BMI) [46]. Normal vitamin D status
is associated with a two-thirds lower prevalence of metabolic
syndrome compared to those with reduced levels [47]. In non-
diabetic Caucasians low vitamin D levels are independently asso-
ciated with insulin resistance [48] and are a predictor of
increased 10-year risk of developing hyperglycemia and insulin
resistance [49]. A vitamin D response element is present in the
insulin gene promoter region, and 1a,25(OH)2D activates tran-
scription of the insulin gene [50]. Both 1a-hydroxylase and the
vitamin D receptor are expressed on pancreatic b cells, with an
association between low vitamin D levels and impaired b cell
function having been suggested [50,51]. Two randomized pla-
cebo-controlled trials have shown that high dose vitamin D sup-
plementation improved insulin sensitivity in non-diabetic South
Asians [52,53]. A large prospective cohort study of women dem-
onstrated that those who received vitamin D supplementation
had a signiﬁcantly lower risk of developing type 2 diabetes [54].
Subjects with NAFLD have lower vitamin D levels when com-
pared with controls. Low vitamin D levels are closely associated
with histologic severity of steatosis, necroinﬂammation, and
ﬁbrosis in NAFLD, independent of age, gender, BMI, Homeostatic
Model Assessment (HOMA)-IR score and presence of metabolic
syndrome [55,56]. These ﬁndings have been conﬁrmed in chil-
dren with NAFLD [57].
In a recent study of Lewis rats with diet-induced (choline-
deﬁcient and iron-supplemented L-amino acid or CDAA) NASH,
phototherapy elevated 25(OH)D, and 1a,25(OH)2D levels while
reducing hepatocyte inﬂammation, ﬁbrosis, and apoptosis when
compared to controls. Phototherapy also improved insulin resis-
tance and increased serum adiponectin in association with
reduced hepatic expression of the proﬁbrotic transforming
growth factor (TGF)-b and a-smooth muscle actin (a-SMA), a
marker of hepatic stellate cell activation. In addition, oral vitamin
D3 supplementation reportedly improved liver histology in a
dose-dependent manner [58]. Furthermore, in a rodent high fat
diet model of NAFLD, vitamin D deﬁciency exacerbated histologic
features of NAFLD, increased insulin resistance, and upregulated
liver tissue expression of genes involved in hepatic inﬂammation
and oxidative stress [59]. Given the above ﬁndings, prospective
studies that assess the impact of vitamin D supplementation on
the histologic features of NASH are warranted as a priority, given
the lack of an effective therapy for this condition.902 Journal of Hepatology 201Vitamin D and liver ﬁbrosis
1a,25(OH)2D has anti-ﬁbrotic effects in lung ﬁbroblasts and
mesenchymal multipotent cells in vitro [60,61], as well as anti-
proliferative and anti-ﬁbrotic effects in both in vitro and in vivo
rat models of liver ﬁbrosis. VDR is expressed by hepatic stellate
cells (HSC) and this expression is upregulated by 1a,25(OH)2D.
In addition, 1a,25(OH)2D suppresses HSC proliferation, and
expression of cyclin D1, tissue inhibitor of metalloproteinase 1
and collagen Ia1 in vitro. In vivo, 1a,25(OH)2D decreases a-SMA
expression and collagen levels, and prevents the development of
cirrhosis by thioacetamide (TAA) [62,63]. A vitamin D level
>50 nmol/Lmay be associatedwith a decreased frequency of rapid
ﬁbrosis progression in CHC [39]. However, the clinical importance
of vitamin D as an anti-ﬁbrotic agent remains to be determined.Vitamin D receptor polymorphisms and liver disease
The vitamin D receptor (VDR) gene is located on chromosome 12.
It encodes a 48 kDa soluble protein that is a member of the
nuclear receptor family of ligand-activated transcription factors.
Common single nucleotide polymorphisms (SNP) of the VDR gene
include FokI (rs10735810), BsmI (rs1544410), ApaI (rs7975232),
and TaqI (rs731236). There is a marked racial variation in the
allele frequency of these VDR polymorphisms [64], but their
inﬂuence on VDR function and signaling is unknown [65]. The
BsmI, ApaI, and TaqI SNPs are all in the 30 region of the VDR gene
and are in linkage disequilibrium with each other [66].
In CHC infection, the bAt [CCA]-haplotype of the BsmI, ApaI,
and TaqI alleles, and the CC genotype of the ApaI allele are asso-
ciated with rapid ﬁbrosis progression, cirrhosis and increased
intrahepatic expression of the ﬁbrosis marker gene MMP-9 [39].
In chronic hepatitis B (HBV) infection, the variation in allele fre-
quency of BsmI, ApaI, and TaqI is associated with HBeAg positivity
and HBV ﬂare [67]. Variation in ApaI, and to a lesser extent TaqI, is
also associated with a higher HBV viral load and more severe
ﬁbrosis and necroinﬂammation [68]. Variation in the TaqI VDR
polymorphism is also associated with both chronic HBV infection
[69] and occult HBV infection [70], in which there is a low degree
of HBV replication present in HBsAg negative subjects.
In hepatocellular carcinoma (HCC), complicating cirrhosis var-
iation in the allele frequency of the BsmI, ApaI, and TaqI, but not
FokI VDR polymorphisms is associated with HCC development
when compared to cirrhotic patients without HCC. This associa-
tion is most marked in subjects with alcohol-related cirrhosis,
where carriage of the BsmI–ApaI–TaqI A–T–C and G–T–T haplo-
types is independently associated with an increased risk of
HCC. Furthermore, there is a signiﬁcant difference in allele fre-
quency of these VDR polymorphisms in alcohol-related cirrhosis
compared to cirrhosis complicating chronic viral hepatitis [66].
Multiple studies have conﬁrmed an association between VDR
polymorphisms and autoimmune liver disease in both European
and Asian populations. Variation in the allele frequency of the
BsmI polymorphism is associated with primary biliary cirrhosis
[71,72], while variation of the FokI polymorphism is associated
with autoimmune hepatitis [64,73]. Furthermore, carriage of
the VDR BsmI–TaqI G–T/G–T diplotype is an independent predic-
tor of acute cellular rejection post-liver transplantation [74]. Sim-
ilarly, VDR polymorphisms are associated with a variety of other
autoimmune and immune-mediated diseases, including type 12 vol. 57 j 897–909
Table 4. Genetic variation in vitamin D and disease.
Target Action
Hepatic
1α-hydroxylase (CYP27B1) gene:
rs10877012 A/C SNP associated with responsiveness to therapy in HCV-1
AA genotype has higher SVR rate and 1α,25(OH)2D level than AC or CC genotype [29]
VDR gene polymorphism associations:
bAt [CCA]-haplotype of BsmI, ApaI and TaqI alleles, and CC genotype of the Apa
infection [69] and occult infection [70]
BsmI-ApaI-TaqI A-T-C and G-T-T haplotypes associated with HCC in alcohol-related cirrhosis [66]
BsmI and PBC [71,72]
FokI and AIH [64,73] 
BsmI-TaqI G-T/G-T diplotype predicts acute rejection post-liver transplantation [74]
Extra-hepatic
VDR gene polymorphism associations:
Immune-mediated diseases: type 1 diabetes [75], leprosy [76], Crohn’s disease [77], TB [69,78,100], psoriasis 
[79], MS [80] and Graves’ disease [81]
Malignancies: melanoma [148] and cancer of the colon [146], ovary [147], breast, prostate and kidney [148]
DBP gene associations:
responses to vitamin D supplementation [132,133]
Vitamin D dependent antimicrobial response of monocytes varies with DBP genotype [96]
Gc2 isoform associated with lower 25(OH)D level [97,98], reduced macrophage function [4] and increased 
progression, cirrhosis and increased intrahepatic expression of fibrosis marker gene MMP-9 [39]
HBV: eAg positivity and flare [67], higher viral load, more severe fibrosis and necroinflammation [68], chronic
Gc1F, Gc1S and Gc2 isoforms of DBP have differing affinities for vitamin D [133,134] and result in variable
susceptibility to active TB in the presence of severe vitamin D deficiency [99]
I allele predicts rapid fibrosis
JOURNAL OF HEPATOLOGYdiabetes [75], leprosy [76], Crohn’s disease [77], tuberculosis
[69,78], psoriasis [79], multiple sclerosis [80], and Graves’ disease
[81] (Table 4).Vitamin D, the immune system, and the liver
There is an increased incidence and prevalence of autoimmune
diseases such as type I diabetes, multiple sclerosis (MS) and Cro-
hn’s disease in geographic regions at higher latitude [82,83]. This
phenomenon is suggested to be related to lower 25(OH)D levels
resulting from decreased ultraviolet sunlight exposure. In sup-
port of this hypothesis, the incidence of MS decreases with
increasing 25(OH)D levels [84] and vitamin D supplementation
decreases the risk of developing both MS in women [85] and type
1 diabetes in children by 80% [86]. In this context, vitamin D has
an important role in both the innate and adaptive immune sys-
tem [87]. Macrophages, T cells, and DCs express both 1a-hydrox-
ylase and vitamin D receptor, and are thus direct targets of
25(OH)D and 1,25(OH)2D [88–90].
Innate immunity
The innate immune response is mediated by pattern-recognition
receptors (PRR). Toll-like receptors (TLR) are a family of trans-
membrane PRRs with broad speciﬁcity, expressed on immune
cells such as polymorphonuclear cells, monocytes, and macro-
phages. They interact with pathogen-associated molecular pat-
terns such as viral nucleic acids, and bacterial and fungal
products, to trigger an inﬂammatory (TNF, IL-1b, and IL-6) orJournal of Hepatology 201antimicrobial response in the host [91]. Several data from studies
focusing on the immunology of mycobacterial infection suggest
vitamin D and DBP play a signiﬁcant part in the activation of
the innate immune response. The risk of Mycobacterium tubercu-
losis (TB) infection is increased in subjects with vitamin D deﬁ-
ciency, with the greatest risk observed in subjects with the
lowest 25(OH)D levels [78,92–94]. At a cellular level, macro-
phages infected with M. tuberculosis initiate a TLR2/1 response
that enhances 1a-hydroxylase and VDR expression and induction
of the anti-microbial peptide cathelicidin. The anti-microbial
activity of macrophages occurs via a vitamin D-dependent pro-
cess. Addition of 1a,25(OH)2D to M. tuberculosis-infected macro-
phages reduces the number of viable bacilli, while both vitamin D
and TLR2/1 are required for cathelicidin production [95]. DBP
plays a key role in modulating monocyte responses to 25(OH)D
and 1a,25(OH)2D, that varies according to the DBP genotype.
Notably, monocytes cultured in serum from DBP null mice, and
in human serum with the lower afﬁnity Gc1S and Gc2 DBP iso-
forms, have more potent induction of cathelicidin than mono-
cytes cultured in serum from DBP+/ mice or human serum
with the high afﬁnity Gc1F isoform [96]. The Gc2 isoform is asso-
ciated with lower 25(OH)D levels [97,98], and carriers of this
allele have an increased susceptibility to active TB in the presence
of severe vitamin D deﬁciency (<20 nmol/L) [99]. The Gc2 isoform
is less able to be converted into macrophage activating factor,
resulting in reduced macrophage function [4]. These data indicate
that vitamin D-dependent antimicrobial responses may be
strongly inﬂuenced by genetic polymorphisms in DBP, especially
in the presence of vitamin D deﬁciency. Moreover, adjunctive
high-dose vitamin D signiﬁcantly hastens the time to sputum cul-2 vol. 57 j 897–909 903
Table 5. Key future research requirements.
Effect of vitamin D supplementation on:
NAFLD
Incidence and outcomes of HCC
Outcomes in OLTx recipients
Prospective, randomized, placebo-controlled studies of vitamin D supplementation as an adjunct to HCV anti-viral therapy
Associations and relevance of genetic polymorphisms in DBP, VDR, 25-hydroxylase and 1-hydroxylase with HBV, HCV, NAFLD and HCC
Liver fibrosis and fibrogenesis
Identification of optimal 25(OH)D level in CLD
Reviewture conversion during intensive-phase antimicrobial treatment
of pulmonary TB in the subset of patients with the tt genotype
of the TaqI VDR polymorphism [100]. In addition, variation in
allele frequency of the FokI and TaqI VDR polymorphisms in the
presence of vitamin D deﬁciency is associated with increased risk
of TB [69,78].
The role of vitamin D in innate immunity has implications on
liver disease. Chronic liver disease is characterized by ongoing
increased exposure of the liver via the portal circulation to bacte-
rial products such as lipopolysaccharide (LPS). Contributing fac-
tors include increased intestinal mucosal permeability, alcohol
ingestion, and small bowel bacterial overgrowth [101–103]. Die-
tary factors, such as a high-fat diet that predisposes to NAFLD,
may also contribute to increased intestinal permeability and
result in increased hepatic exposure to LPS [104]. Kupffer cells,
the resident macrophages of the liver, represent 80–90% of the
macrophages in the body [105], and their innate immune vitamin
D-dependent antimicrobial response is also likely to be inﬂuenced
by the vitamin D status and genetic polymorphisms in DBP. They
also express TLR2, TLR4, and TLR9, and are responsive to LPS, the
main ligand of TLR4. Hepatocytes, hepatic stellate cells, sinusoidal
epithelial cells, biliary epithelial cells, and hepatic DCs also
express TLR4 and are responsive to LPS. The interaction of LPS
with TLR4 in the liver is crucial during hepatic ﬁbrogenesis
[101,106]. Serum vitamin D levels are inversely proportional to
TLR2 and TLR4 expression in monocytes, with administration of
1a,25(OH)2D downregulating expression of TLR2, TLR4, and
TLR9 [107–110]. Intestinal microbiota play an essential role in
hepatic fat accumulation. TLR2, TLR4, and TLR9 are implicated in
the pathogenesis of NAFLD, with TLR4 and TLR9 signaling associ-
ated with worsening steatosis, inﬂammation and ﬁbrosis
[111,112]. In obese rats, vitamin D deﬁciency increases hepatic
mRNA levels of TLR2, TLR4, and TLR9, and the endotoxin receptor
CD14, which is implicated in worsening histologic features of
NAFLD [59]. In CHC infection, increasing hepatic necroinﬂamma-
tory activity correlates with increasing hepatic mRNA expression
of TLR2 and TLR4, and hepatic TNFa mRNA is also closely
correlated with TLR2 and TLR4 mRNA expression [113]. Further-
more, the antiviral effect of vitamin D on hepatitis C inoculated
HuH7.5 hepatoma cells is mediated by innate immune
system activation of the interferon-mediated signaling pathways
[30].
NK cells and DCs are both important innate immune effector
cells. Studies in VDR knockout mice have shown that expression
of VDR is necessary for NK cell development and function [114].
1a,25(OH)2D enhances NK cell cytotoxicity [115] and suppresses
DC maturation, inducing a more tolerant DC phenotype which, at
the interface of the innate and adaptive immune systems, pro-
motes T regulatory (Treg, CD4+CD25+) cell activity [116].904 Journal of Hepatology 201Adaptive immunity
Vitamin D is an important modulator of T cell response to patho-
gens, which is a key component of adaptive immunity. In partic-
ular, activation of naïve T cells is a vitamin D-dependent process.
In the inactivated state, naïve T cells do not express VDR and
express almost no phospholipase C-c1 (PLCc1), which is a key
molecule required for subsequent classical T cell receptor signal-
ing and T cell activation. Following stimulus exposure, VDR is
expressed on T cells through T cell receptor signaling via the
alternative mitogen-activated kinase p38 pathway. The VDR
complex, activated by binding of 1a,25(OH)2D, upregulates tran-
scription of the gene encoding PLCc1 and results in a 75-fold
increase in PLCc1 expression, enabling activation of naïve T cells.
T cells in patients with lower 25(OH)D and 1a,25(OH)2D levels
have a lower proliferation index after stimulation than T cells
from patients with normal 25(OH)D and 1a,25(OH)2D levels; this
pattern is overcome by exogenous administration of
1a,25(OH)2D [117].
1a,25(OH)2D also has an anti-proliferative effect on adaptive
immunity. It inhibits proliferation of T helper type 1 (Th1) lym-
phocytes, which produce interferon (IFN)-c, interleukin (IL)-2,
and activate macrophages [118], and shifts the balance to a T
helper type 2 (Th2) phenotype with increased production of
IL-4, IL-5, and IL-10 [119]. 1a,25(OH)2D increases Treg cells
[120,121], enhances DC secretion of IL-10, decreases DC secretion
of IL-12, a critical cytokine in Th1 development [122], and inhib-
its Th17 development via inhibition of IL-6 and IL-23 production
[121]. In patients with MS, 25(OH)D, but not 1a,25(OH)2D, levels
correlate with the ability of Treg cells to suppress the prolifera-
tion of activated T responder cells and inversely correlated with
Th1/Th2 ratio [123]. IL-2, IL-10, and IL-12 genes in T cells have
regions which bind to VDR and 1a,25(OH)2D may directly play
a role in the transcription of these cytokines in T cells [124].
The ability of 1a,25(OH)2D to modulate the adaptive immune
system may explain the association of vitamin D supplementa-
tion and higher 25(OH)D levels with a lower risk of multiple
autoimmune diseases.
In orthotopic liver transplant recipients, severe 25(OH)D deﬁ-
ciency (<12.5 nmol/L) and VDR BsmI–TaqI G–T/G–T diplotype are
independent predictors of moderate-severe acute cellular rejec-
tion, whilst vitamin D3 supplementation decreases the risk of
acute rejection by 60% [74,125]. These ﬁndings highlight the
importance of optimizing the vitamin D status in liver transplant
recipients, not only to prevent bone loss, but also to reduce the
risk of T cell-mediated acute rejection. A lower Th1/Th2 ratio is
an independent predictor of SVR in treatment of HCV-1 [126],
which possibly explains why vitamin D supplementation may
improve therapeutic outcomes with PEG-IFN plus RBV. The2 vol. 57 j 897–909
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immune tolerant phenotype promoted by vitamin D may also be
of therapeutic beneﬁt in NASH, where activation of both innate
and adaptive immunity is implicated in its pathogenesis.Genome wide association studies of vitamin D
Only about a quarter of vitamin D variability between individuals
is explained by factors such as reported dietary intake, latitude
and season of measurement [127,128]. Twin and family studies
suggest that genetic factors play a signiﬁcant role in the wide var-
iation of vitamin D levels observed within and between popula-
tions [129]. Polymorphisms of the hydroxylases, DBP, and VDR
may have a profound inﬂuence on serum vitamin D levels and
the efﬁcacy of vitamin D as a hormone. Two large genome wide
association studies (GWAS), involving patients of European
ancestry [130,131], of SNPs and their association with 25(OH)D
levels have revealed important information about genetic varia-
tion in the enzymes and carrier proteins which are integral to
the synthesis and metabolism of vitamin D.
The NADSYN1/DHCR7 locus is closely related to the de novo
synthesis of vitamin D3 in the skin from the precursor 7-dehydro-
cholesterol. There is an association between 25(OH)D levels and
several SNPs including rs12785878, rs12800438, rs3794060,
rs4945008, and rs4944957 of this locus [124]. SNPs in the 25-
hydroxylase CYP2R1 locus rs10741657, rs2060793, rs12794714,
rs10500804, and rs7116978 are also signiﬁcantly associated with
25(OH)D levels [128,129].
The highly polymorphic vitamin D-binding protein binds the
majority of 25(OH)D and 1a,25(OH)2D. DBP is predominantly
produced in the liver, but also in kidney, gonads, fat, and neutro-
phils. SNPs in the DBP locus associated with 25(OH)D levels are
rs2282679, rs7041, rs3755967, rs17467825, rs2298850, and
rs1155563 [124–126]. Response to vitamin D supplementation
may vary with differing genotypes of DBP [132,133]. In addition
to the three common isoforms Gc1F, Gc1S, and Gc2, there are
>120 rare variants of DBP. Haplotypes of the SNPs rs4588 and
rs7041 in exon 11 of the gene result in the Gc1F, Gc1S, and Gc2
isoforms, which have differing afﬁnities for vitamin D [134].
The DBP SNP rs2282679, which has the strongest association with
vitamin D levels, lies in intron 12 near the actin subdomain III
and may affect DBP binding of 25(OH)D [131].
24-hydroxylase (CYP24A1) is primarily responsible for the
inactivation of 25(OH)D and 1a,25(OH)2D. The SNP rs6013897
from this locus is also associated with vitamin D levels [130].
These studies highlight the importance of genetic variation in
vitamin D status and may explain in part the varying response
seen to vitamin D supplementation. Polymorphisms in four spe-
ciﬁc loci involved in vitamin D synthesis and metabolism have
a signiﬁcant impact on circulating 25(OH)D levels in patients of
European ancestry. Further GWAS that include patients of more
diverse racial backgrounds may reveal more genetic associations
with the vitamin D status.Vitamin D and cancer
Vitamin D is also associated with the development of neoplasia.
Higher 25(OH)D levels are associated with a lower risk of inci-
dent left-sided colorectal adenomas [135]. Multiple meta-analy-Journal of Hepatology 201ses, and large prospective and retrospective observational
studies have established that vitamin D deﬁciency is associated
with an increased risk of colon [136–139], breast [140–142],
and prostate cancer [143,144]. Furthermore, increased sunlight
exposure is associated with a reduced risk of non-Hodgkin’s lym-
phoma [145] and VDR polymorphisms are associated with adeno-
carcinoma in the colon [146], ovary [147], breast, prostate, renal
cell carcinoma, and melanoma [148]. With respect to the liver, a
variety of VDR polymorphisms are associated with the develop-
ment of HCC in at-risk patients as detailed above. However, it
remains unclear as to whether vitamin D deﬁciency is associated
with an increased risk of HCC.Conclusions
Vitamin D deﬁciency is a common problem in chronic liver dis-
ease and is closely associated with disease severity. The anti-
inﬂammatory and immune-modulatory properties of vitamin
D provide plausible mechanisms by which vitamin D may
impact on disease progression and severity, especially in CHC
and NASH. However, there are few prospective studies evaluat-
ing the effect of vitamin D supplementation in chronic liver
disease and these are clearly warranted in the areas of NASH
and CHC based on preclinical, and limited retrospective and
prospective clinical data. Genetic polymorphisms of the vitamin
D receptor and of proteins and enzymes involved in vitamin D
synthesis and activation have an association with vitamin D
status and severity of liver disease. Further studies are also
warranted in this area, to conﬁrm known associations and
evaluate other genetic polymorphisms, especially in the vita-
min D binding protein, which plays a key role in vitamin D
synthesis, activity and bioavailability (Table 5). In the interim
period, we recommend vitamin D status to be assessed in all
patients with CLD and, if deﬁciency is present (<50 nmol/L or
20 ng/ml), supplementation with 1000–4000 IU/day of vitamin
D3 should be initiated, with the initial dose dependent upon
baseline 25(OH)D levels. However, increasing evidence suggests
that supplementation should be considered for a 25(OH)D level
<75 nmol/L, especially in those considering interferon-based
antiviral therapy for CHC. Further prospective studies are
required to identify an optimal 25(OH)D level in subjects with
CLD.
Key Points 
• Extra-skeletal effects of vitamin D include 
properties
• 
• 
response to antiviral therapy in CHC
• Vitamin D supplementation may improve SVR to 
interferon-based antiviral therapy in CHC genotypes 1, 
2 and 3
• 
severity of NAFLD
• Vitamin D is a plausible therapy for NAFLD because 
of its insulin-sensitizing, immunomodulatory, anti-
immunomodulatory, anti-inflammatory, and anti-fibrotic
Vitamin D deficiency is frequently present in CLD
Vitamin D deficiency may independently predict non-
Vitamin D deficiency is associated with the histologic
inflammatory, and anti-fibrotic properties2 vol. 57 j 897–909 905
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